Search research articles
Contact Us
Filters
Showing results (1-10 of 27) with videos related to
Page
of 3
Sort By:
Annals of the Royal College of Surgeons of England
|
April 1, 2010
Comment on: Clarity of language
Chris Day
Clinical Liver Disease
|
April 18, 2019
Natural history and factors influencing the course of alcohol-related liver disease
Stuart Kendrick, Chris Day
Imprint
|
March 5, 2004
Nurses strengthen the fabric of public health
Chris Day, Marcia Stanhope
Gut
|
October 17, 2009
Childhood NAFLD: a ticking time-bomb?
Valerio Nobili, Chris Day
Clinical Medicine (London, England)
|
November 5, 2009
Britain's alcohol market: how minimum alcohol prices could stop moderate drinkers subsidising those drinking at hazardous and harmful levels
Chris Record, Chris Day
Digestive Diseases (Basel, Switzerland)
|
July 19, 2014
Treatment of non-alcoholic fatty liver disease
Jessica Dyson, Chris Day
Journal of Hepatology
|
June 4, 2015
Sugar sweetened beverages and fatty liver disease: Rising concern and call to action
Manal F Abdelmalek, Chris Day
BMJ (Clinical Research Ed.)
|
October 13, 2016
Authors' reply to Tavabie
Chris Day, Jessica Glen, Lefteris Floros, et al.
Current Pharmaceutical Design
|
February 12, 2013
From NAFLD to NASH and HCC: pathogenetic mechanisms and therapeutic insights
Samuele De Minicis, Chris Day, Gianluca Svegliati-Baroni
BMJ (Clinical Research Ed.)
|
September 9, 2016
Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance
Jessica Glen, Lefteris Floros, Chris Day, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 27) with videos related to
Sort By:
Page
of 3
Annals of the Royal College of Surgeons of England
|
April 1, 2010
Comment on: Clarity of language
Chris Day
Clinical Liver Disease
|
April 18, 2019
Natural history and factors influencing the course of alcohol-related liver disease
Stuart Kendrick, Chris Day
Imprint
|
March 5, 2004
Nurses strengthen the fabric of public health
Chris Day, Marcia Stanhope
Gut
|
October 17, 2009
Childhood NAFLD: a ticking time-bomb?
Valerio Nobili, Chris Day
Clinical Medicine (London, England)
|
November 5, 2009
Britain's alcohol market: how minimum alcohol prices could stop moderate drinkers subsidising those drinking at hazardous and harmful levels
Chris Record, Chris Day
Digestive Diseases (Basel, Switzerland)
|
July 19, 2014
Treatment of non-alcoholic fatty liver disease
Jessica Dyson, Chris Day
Journal of Hepatology
|
June 4, 2015
Sugar sweetened beverages and fatty liver disease: Rising concern and call to action
Manal F Abdelmalek, Chris Day
BMJ (Clinical Research Ed.)
|
October 13, 2016
Authors' reply to Tavabie
Chris Day, Jessica Glen, Lefteris Floros, et al.
Current Pharmaceutical Design
|
February 12, 2013
From NAFLD to NASH and HCC: pathogenetic mechanisms and therapeutic insights
Samuele De Minicis, Chris Day, Gianluca Svegliati-Baroni
BMJ (Clinical Research Ed.)
|
September 9, 2016
Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance
Jessica Glen, Lefteris Floros, Chris Day, et al.
Page
of 3